Compare Amphastar Pharmaceuticals Inc (AMPH) vs Alibaba Group (BABA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Alibaba (BABA) trades at $112.33, up 1.07% today, with a bullish technical signal and strong analyst consensus. Recent earnings misses contrast with improving fundamentals, including a 13.05% net margin and $130.11B net income for 2025. The stock faces headwinds from securities investigations but benefits from AI momentum and narrowing losses in quick commerce.

Outlook remains positive with an 86% buy rating and $195 consensus target, though risks include regulatory scrutiny and earnings volatility. Upside potential hinges on execution in cloud and e-commerce, while legal overhangs and macroeconomic pressures pose near-term challenges.